News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

November 2009

Intranasal Fentanyl Spray Effective for Breakthrough Cancer Pain

March 9th 2010

Using Ultrasound to Guide Treatment and Predict Survival in Patients with Melanoma

March 9th 2010

Researchers Propose Standard of Care for Patients with Partially Platinum-Sensitive Ovarian Cancer

March 9th 2010

Chemoradiotherapy Improves PFS in Nasopharyngeal Cancer & Treatment-related Deaths

March 9th 2010

Kidney Cancer Targeted with New VEGF Inhibitor

March 9th 2010

Alpha-Emitting Pharmaceutical Shows Novel Results in Bone Metastases

March 9th 2010

Two New Blood Tests Improve Early Detection of GI and Colorectal Cancers

March 9th 2010

Preoperative Chemotherapy Superior to Postoperative Chemotherapy in 5-Year Disease-free Survival for NSCLC Patients

March 9th 2010

The World Comes Together Over Cancer

March 9th 2010

Trending on OncLive

In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas

Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC

Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026

Emiltatug Ledadotin Elicits Responses in Aggressive Adenoid Cystic Carcinoma

A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety